To assess the role of TRIM5α and CypA in the primary human blood cell types 1 that serve as targets for HIV-1 infection in vivo, lentiviral vectors were optimized for titer 2 and knockdown efficiency in these cells 26, [31] [32] [33] [34] . Human macrophages, dendritic cells, 3 and CD4 + T cells were transduced with lentivectors bearing a puromycin resistance 4 cassette and shRNAs targeting either TRIM5 or luciferase (Luc) as a control. After three 5 days of selection in puromycin, knockdown was confirmed by RT-qPCR for TRIM5 6 mRNA, and by rescue of N-MLV restriction (Extended Data Fig. 2a-c) , as done 7 previously 26, 31 . TRIM5 and Luc control knockdown cells were then challenged with 8 single-cycle, VSV G-pseudotyped, HIV-1-GFP reporter vectors. Three days later, the 9 percentage of GFP + cells was assessed by flow cytometry as a measure of infectivity 10 (Extended Data Fig. 1 shows the gating strategy).
11
As compared with Luc control knockdown, TRIM5 knockdown had minimal effect 12 on HIV-1 transduction efficiency in macrophages, dendritic cells, or CD4 + T cells (Fig. 13 1a-d; Extended Data Fig. 3a) . Infectivity of HIV-1 CA-P90A, a mutant that disrupts CypA 14 binding 8, 9 , was significantly attenuated in control knockdown cells generated with all 15 three cell types ( Fig. 1a-d ). The effect was evident in cells from all blood donors tested 16 (at least three blood donors per condition) and over a 100-fold range in challenge vector 17 titer (Extended Data Fig. 3a ). TRIM5 knockdown in macrophages, dendritic cells, or 18 
CD4
+ T cells increased CA-P90A infectivity ( Fig. 1a-d ; Extended Data Fig 3a) . Results
19
were the same whether challenge was with a three-plasmid vector system based on the 20 clade B HIV-1NL4-3 lab strain 33, 35 ( Fig. 1a-c) , or a two plasmid vector system based on 21 the clade C HIV-1ZM249M transmission-founder strain from Zambia 33, 36 (Fig. 1d) . 22 Given previous reports that CypA and TRIM5 act independently to regulate HIV-1 23 transduction of immortalized cell lines 26 , the rescue of CA-P90A infectivity by TRIM5 24 knockdown in primary human blood cells was surprising. Complementary 25 pharmacologic and reverse genetic approaches were therefore taken to disrupt the CA- 26 CypA interaction. For pharmacologic disruption, cells were incubated in media 27 containing small molecules that compete with CA for binding to CypA 2, [8] [9] [10] 37 . As 28 compared with DMSO solvent alone, cyclosporine A (CsA) reduced HIV-1 transduction 29 efficiency in control Luc knockdown macrophages (Fig. 1e ). In contrast, cyclosporine H, 30 an analogue with 1,000-fold lower affinity for CypA 38 inhibition in macrophages caused by CsA (Fig. 1e) , or in CD4 + T cells caused by the 4 sanglifehrin A-derivatives ( Fig. 1f ; Extended Data Fig. 3c -e).
5
To disrupt the CA-CypA interaction using a genetic approach, macrophages were 6 transduced with two vectors. addition to an shRNA (Fig. 2a) . Four variants of the plasmid were engineered in which 24 the shRNA targeted either TRIM5 or Luc, with or without a TRIM5α coding sequence 25 that bears mismatches in the shRNA target sequence (Fig. 2a) . 26 Macrophages (Fig. 2b ) and CD4 + T cells (Fig. 2c) were transduced with each of 27 the four variants of the shRNA tripartite fusion vector and selected for three days with 28 puromycin. Cells were then challenged with the three-plasmid HIV-1-GFP reporter 29 vector used in Fig. 1a , and assessed by flow cytometry for percent GFP positive cells 30 three days later. As in Fig. 1 , the infectivity of vector bearing wild-type CA was minimally 31 affected by TRIM5 knockdown, or by TRIM5 overexpression (Fig. 2b, c) . As compared 1 to the wild-type, the infectivity of vector bearing CA-P90A was decreased (Fig. 2b, c) , 2 and the infectivity of this mutant was rescued by TRIM5 shRNA (Fig. 2b, c 40 . DNA was collected 20 hrs post-challenge and qPCR was 16 performed using primers specific for full-length linear HIV-1 cDNA (late RT). In all 17 experiments, reporter vector bearing the RT-D185K/D186L loss-of-function mutation 40 
18
was included as a control for background signal not due to nascent reverse transcription 19 ( Fig. 3) . 20 In Luc control knockdown macrophages and CD4 + T cells, viral cDNA was 21 reduced by CA-P90A, and this reduction was restored by TRIM5 knockdown (Fig. 3a,   22 b). Viral cDNA was also reduced by CA-P90A in either cell type transduced with the 23 control shRNA tripartite fusion vector (Fig. 3c, d ). TRIM5 shRNA rescued the cDNA 24 ( Fig. 3a-d) , and rescue of TRIM5α with the non-targetable coding sequence again 25 decreased the CA-P90A cDNA (Fig. 3c, d ). CsA, very few puncta were detected ( Fig. 4a, b ; Extended Data Fig. 4) . Similarly, few 4 puncta were detected when cells were treated with CsA in the absence of HIV-1 5 challenge. In contrast, when cells were challenged with HIV-1 in the presence of CsA, 6 multiple puncta were detected (Fig. 4a, b) , an increase of at least 20-fold in the average 7 number of puncta per cell over the background ( with HIV-1 CA when the CA-CypA interaction is disrupted.
12
The above experiments used exogenous, single-cycle HIV-1 vectors. The effect 13 of CypA on HIV-1 restriction by human TRIM5α was therefore evaluated next using The experiments presented here demonstrate that, in primary human blood cells, All plasmids used here are described in Supplementary Table 1, and are available,   4 along with full sequences, at https://www.addgene.org/Jeremy_Luban/. analysis on the assumption that these were out of the linear range, according to the 28 Poisson distribution. 29 
30

Statistical analysis
Experimental n values and information regarding the statistical tests can be found in the 1 figure legends. The data of infectivity assay using single-cycle viruses including at least 2 three independent donors were statistically analyzed by using two-tailed paired t-test 3 compared to the control condition or the indicated condition for each donor. The data of 4 PLA quantification were assessed for statistical significance using two-tailed unpaired t- 5 test to compare two conditions as indicated in Fig. 4 . All statistical analyses were 6 performed using PRISM 7.0 (GraphPad Software, La Jolla, CA). Quantitative PCR for viral late reverse transcriptase product 9 Total DNA was extracted from cells using DNeasy Blood & Tissue Kit (Qiagen, Hilden, 10 Germany), following the manufacturer's instruction. Late RT products were detected 11 with TaqMan system using the primers pWPTS J1B fwd and pWPTS J2 rev with the late 12 RT probe (LRT-P) 44 . Mitochondrial DNA was used for normalization with the following 13 primer/probe set: MH533, MH534 and Mito probe 45 . The primer and probe sequences 14 are specified in Supplementary CypA (1:10,000 dilution; Enzo Life Sciences, Farmingdale, NY, catalogue #BML-SA296) 12 and mouse anti-β-actin (1:1,000 dilution; Abcam, Cambridge, UK, catalogue #ab3280).
13
Goat anti-mouse-680 (Li-Cor, catalogue #925-68070) and goat anti-rabbit-800 (Li-Cor, 14 catalogue #925-32211) as secondary antibodies were used at 1:10,000 dilutions. Blots 15 were scanned on the Li-Cor Odyssey CLx. Author information The authors declare no competing financial interests.
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